How Much Does Medical Weight Loss Cost in Ann Arbor, MI?

What Does Medical Weight Loss Actually Cost in 2026?

The cost of medical weight loss depends on three factors: which medication you use, whether you have insurance coverage, and how your provider structures their program. Here is a realistic breakdown of what Ann Arbor patients can expect.

Brand-Name GLP-1 Medication Prices

At retail (without insurance), monthly costs for the leading GLP-1 medications are significant:

*Ozempic and Mounjaro are FDA-approved for type 2 diabetes; Wegovy and Zepbound are the weight-management formulations of the same molecules.

Compounded GLP-1 Pricing

Compounded versions, available through licensed 503B compounding pharmacies, offer substantially lower price points:

It is important to note that compounded medications are prepared for individual patients by licensed pharmacies rather than mass-produced as finished drug products. At Arbour Longevity, we work only with verified, FDA-registered compounding pharmacies to ensure quality and safety for our patients.

What Is Included in Arbour Longevity's Medical Weight Loss Program?

The cost of medication is only part of the picture. A responsible medical weight loss program includes clinical oversight that makes the treatment safer and more effective. At Arbour Longevity, our program includes:

• Comprehensive initial consultation - A thorough review of your health history, current medications, metabolic health, and weight loss goals with Gandhi Bhattarai, FNP-BC, PMHNP-BC
• Baseline and ongoing lab work - Metabolic panels, thyroid function, HbA1c, lipid panels, and other labs to monitor your health throughout treatment
• Personalized medication management - Dose titration, side-effect management, and adjustments based on your response
• Regular follow-up consultations - Ongoing clinical check-ins to track progress, adjust the plan, and address challenges
• Nutritional and lifestyle guidance - Evidence-based recommendations to maximize weight loss results and support long-term maintenance
• Coordination with complementary therapies - Integration with bioidentical hormone replacement therapy (BHRT) or peptide therapy when clinically appropriate

This comprehensive approach matters because the clinical evidence is clear: GLP-1 medications produce their best results under medical supervision. According to PubMed, the STEP 5 trial demonstrated that semaglutide 2.4 mg produced a mean body weight reduction of 15.2% over two years, compared to just 2.6% with placebo (DOI: 10.1038/s41591-022-02026-4). The SURMOUNT-1 trial found that tirzepatide at its highest dose achieved an average weight reduction of 20.9% over 72 weeks (DOI: 10.1056/NEJMoa2206038). These results were achieved in clinical settings with regular monitoring and dose management - exactly the kind of structured program we provide.

Insurance Coverage: The Real Picture

Insurance coverage for GLP-1 weight loss medications remains inconsistent in 2026. Here is what you need to know:

Commercial Insurance

Coverage varies widely by plan. Some employer-sponsored plans cover Wegovy or Zepbound with prior authorization, while others explicitly exclude anti-obesity medications. If your plan does cover these medications, manufacturer savings cards (from Novo Nordisk and Eli Lilly) can reduce copays to as low as $25 per month for eligible patients.

A practical tip: if your initial claim is denied, request a peer-to-peer review. Current data suggests insurance denial reversal rates of 30–50% when proper clinical documentation is provided.

Medicare Part D

Medicare has historically excluded medications prescribed specifically for weight loss. However, 2026 brings a meaningful change: the Medicare GLP-1 Bridge program, launching July 1, 2026, covers Wegovy, Zepbound, and Foundayo at a flat $50 per month copay. This is the first time Medicare has directly paid for weight loss medication. Additionally, the 2026 Part D out-of-pocket cap of $2,100 per year protects seniors from catastrophic drug costs.

GLP-1 medications remain fully covered under standard Part D for type 2 diabetes, cardiovascular risk reduction in patients with established heart disease, and obstructive sleep apnea.

Michigan Medicaid: Major Changes for 2026

Effective January 1, 2026, Michigan's Healthy Michigan Plan significantly restricted coverage of GLP-1 medications for weight management. This change, mandated by the state's fiscal year 2026 budget, affects Saxenda, Wegovy, and Zepbound for weight loss indications.

The new requirements include:

• Coverage is now limited to beneficiaries with a BMI of 40 or higher (previously, lower thresholds qualified)
• Providers must document that other weight loss interventions have failed (such as phentermine or Qsymia)
• Documentation is required showing that GLP-1 use is necessary to avoid bariatric surgery
• Existing beneficiaries lose coverage when their current six-month authorization expires

According to researchers at the University of Michigan, this policy could affect up to one million low-income Michiganders and is projected to save the state $240 million in 2026. Experts have raised concerns about worsening health disparities, since obesity disproportionately affects low-income and minority populations.

GLP-1 medications remain covered under Michigan Medicaid for type 2 diabetes, established cardiovascular disease, severe sleep apnea, and severe liver disease.

For Ann Arbor patients affected by these changes, Arbour Longevity offers alternative pricing structures to help maintain continuity of care.

Why Supervised Medical Weight Loss Is Worth the Investment

It is tempting to focus purely on the monthly medication cost, but the clinical evidence supports a more complete view. Based on articles retrieved from PubMed, the STEP 4 trial demonstrated that patients who continued semaglutide treatment lost an additional 7.9% of body weight over 48 weeks, while those who stopped treatment regained an average of 6.9% - a swing of nearly 15 percentage points (DOI: 10.1001/jama.2021.3224). This underscores why ongoing clinical management and a planned maintenance strategy are essential, not optional extras.

The cost of untreated obesity is also substantial. Obesity-related healthcare costs average $1,861 more per person per year compared to individuals at a healthy weight. When you factor in reduced medication needs for blood pressure, cholesterol, and blood sugar management, the return on investment in medical weight loss becomes compelling.

Financing Options and Making Treatment Accessible

We understand that even with competitive pricing, medical weight loss is a financial commitment. Here are the options available to Ann Arbor patients:

• HSA and FSA accounts - Medical weight loss prescribed by a provider is typically an eligible expense for Health Savings Accounts and Flexible Spending Accounts
• Manufacturer savings programs - Novo Nordisk's NovoCare program (for Wegovy) and Eli Lilly's LillyDirect program (for Zepbound) offer reduced self-pay pricing
• Payment plans - Ask about monthly payment structures that spread costs over your treatment period
• Insurance advocacy - Our team assists with prior authorizations and appeals to maximize your coverage

Start With a $35 Consultation

The most cost-effective first step is knowing whether medical weight loss is right for you before committing to a full program. Arbour Longevity offers a $35 initial consultation with Gandhi Bhattarai, FNP-BC, PMHNP-BC, that includes:

• A comprehensive health and metabolic assessment
• Review of your medication history and current prescriptions
• Discussion of which GLP-1 medication (semaglutide vs. tirzepatide) may be the best fit for your body and goals
• A clear cost breakdown personalized to your insurance situation
• An honest conversation about whether you are a good candidate for treatment

There is no obligation to start a program after the consultation. The goal is to give you the clinical information and cost clarity you need to make a confident decision. Schedule your consultation today.

Frequently Asked Questions

Is medical weight loss tax deductible?

In many cases, yes. If your provider prescribes medical weight loss treatment for a diagnosed condition such as obesity (BMI 30+) or overweight with comorbidities, the costs may qualify as a deductible medical expense on your federal taxes. This includes consultation fees, lab work, and prescription medications. Consult your tax professional for guidance specific to your situation.

How long do I need to take GLP-1 medication?

Current clinical evidence suggests that GLP-1 medications work best as a long-term treatment. The STEP 4 trial showed that patients who discontinued semaglutide regained significant weight within 48 weeks (DOI: 10.1001/jama.2021.3224). At Arbour Longevity, we develop individualized maintenance plans that may include dose reduction, transition to complementary therapies like peptide therapy, and ongoing lifestyle strategies to sustain your results at a lower cost over time.

What is the difference between semaglutide and tirzepatide?

Semaglutide (brand names: Wegovy, Ozempic) is a GLP-1 receptor agonist. Tirzepatide (brand names: Zepbound, Mounjaro) is a dual GIP and GLP-1 receptor agonist, meaning it acts on two hormonal pathways instead of one. The SURMOUNT-1 trial found that tirzepatide at the 15 mg dose produced average weight loss of 20.9%, compared to roughly 15% with semaglutide in the STEP trials (DOI: 10.1056/NEJMoa2206038). However, individual responses vary, and the best choice depends on your health profile, tolerance, and budget. This is exactly what we assess during your consultation.

Does Arbour Longevity accept insurance for weight loss treatment?

We assist patients with insurance verification and prior authorizations for GLP-1 medications. Coverage depends on your specific plan. During your $35 consultation, we review your insurance benefits and provide a clear picture of your expected out-of-pocket costs before you commit to treatment.

Can I combine GLP-1 weight loss medication with other treatments at Arbour Longevity?

Yes. Many of our patients benefit from a multi-modal approach. Bioidentical hormone replacement therapy (BHRT) can address hormonal imbalances that contribute to weight gain and metabolic slowdown, particularly during perimenopause and andropause. Peptide therapy may support lean muscle preservation, recovery, and metabolic optimization alongside your weight loss program. Gandhi Bhattarai, FNP-BC, PMHNP-BC, evaluates each patient individually to determine whether combination therapy is appropriate.